dfpk: An R-package for Bayesian dose-finding designs using pharmacokinetics (PK) for phase I clinical trials

被引:6
|
作者
Toumazi, A. [1 ]
Comets, E. [2 ,3 ]
Alberti, C. [4 ]
Friede, T. [5 ]
Lentz, F. [6 ]
Stallard, N. [7 ]
Zohar, S. [1 ]
Ursino, M. [1 ]
机构
[1] Univ Paris 06, Univ Paris 05, UMRS 1138, INSERM,CRC,Team 22, Paris, France
[2] Univ Rennes 1, INSERM, CIC 1414, Rennes, France
[3] Univ Paris Diderot, INSERM, IAME UMR 1137, Paris, France
[4] Univ Paris 07, Hop Robert Debre, AP HP, INSERM,UMR 1123, Paris, France
[5] Univ Med Ctr Gottingen, Dept Med Stat, Gottingen, Germany
[6] Fed Inst Drugs & Med Devices, Bonn, Germany
[7] Univ Warwick, Warwick Med Sch, Div Hlth Sci, Stat & Epidemiol, Warwick, England
关键词
Dose-finding; Maximum tolerated dose; Pharmacokinetics; Phase I clinical trials; R package; ESCALATION;
D O I
10.1016/j.cmpb.2018.01.023
中图分类号
TP39 [计算机的应用];
学科分类号
081203 ; 0835 ;
摘要
Background and objective: Dose-finding, aiming at finding the maximum tolerated dose, and pharmacokinetics studies are the first in human studies in the development process of a new pharmacological treatment. In the literature, to date only few attempts have been made to combine pharmacokinetics and dose-finding and to our knowledge no software implementation is generally available. In previous papers, we proposed several Bayesian adaptive pharmacokinetics-based dose-finding designs in small populations. The objective of this work is to implement these dose-finding methods in an R package, called dfpk. Methods: All methods were developed in a sequential Bayesian setting and Bayesian parameter estimation is carried out using the rstan package. All available pharmacokinetics and toxicity data are used to suggest the dose of the next cohort with a constraint regarding the probability of toxicity. Stopping rules are also considered for each method. The ggplot2 package is used to create summary plots of toxicities or concentration curves. Results: For all implemented methods, dfpk provides a function (nextDose) to estimate the probability of efficacy and to suggest the dose to give to the next cohort, and a function to run trial simulations to design a trial (nsim). The sim. data function generates at each dose the toxicity value related to a pharmacokinetic measure of exposure, the AUC, with an underlying pharmacokinetic one compartmental model with linear absorption. It is included as an example since similar data-frames can be generated directly by the user and passed to nsim. Conclusion: The developed user-friendly R package dfpk, available on the CRAN repository, supports the design of innovative dose-finding studies using PK information. (C) 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)
引用
收藏
页码:163 / 177
页数:15
相关论文
共 50 条
  • [1] Dose-finding methods for Phase I clinical trials using pharmacokinetics in small populations
    Ursino, Moreno
    Zohar, Sarah
    Lentz, Frederike
    Alberti, Corinne
    Friede, Tim
    Stallard, Nigel
    Comets, Emmanuelle
    BIOMETRICAL JOURNAL, 2017, 59 (04) : 804 - 825
  • [2] bcrm: Bayesian Continual Reassessment Method Designs for Phase I Dose-Finding Trials
    Sweeting, Michael
    Mander, Adrian
    Sabin, Tony
    JOURNAL OF STATISTICAL SOFTWARE, 2013, 54 (13): : 1 - 26
  • [3] Innovations for phase I dose-finding designs in pediatric oncology clinical trials
    Doussau, Adelaide
    Geoerger, Birgit
    Jimenez, Irene
    Paoletti, Xavier
    CONTEMPORARY CLINICAL TRIALS, 2016, 47 : 217 - 227
  • [4] Competing designs for drug combination in phase I dose-finding clinical trials
    Riviere, M. -K.
    Dubois, F.
    Zohar, S.
    STATISTICS IN MEDICINE, 2015, 34 (01) : 1 - 12
  • [5] Bayesian hybrid dose-finding design in phase I oncology clinical trials
    Yuan, Ying
    Yin, Guosheng
    STATISTICS IN MEDICINE, 2011, 30 (17) : 2098 - 2108
  • [6] An R package UnifiedDoseFinding for continuous and ordinal outcomes in Phase I dose-finding trials
    Pan, Haitao
    Mu, Rongji
    Hsu, Chia-Wei
    Zhou, Shouhao
    COMMUNICATIONS FOR STATISTICAL APPLICATIONS AND METHODS, 2022, 29 (04) : 421 - 439
  • [7] A robust Bayesian dose-finding design for phase I/II clinical trials
    Liu, Suyu
    Johnson, Valen E.
    BIOSTATISTICS, 2016, 17 (02) : 249 - 263
  • [8] A comparison of phase I dose-finding designs in clinical trials with monotonicity assumption violation
    Abbas, Rachid
    Rossoni, Caroline
    Jaki, Thomas
    Paoletti, Xavier
    Mozgunov, Pavel
    CLINICAL TRIALS, 2020, 17 (05) : 522 - 534
  • [9] A Bayesian dose-finding design for phase I/II clinical trials with nonignorable dropouts
    Guo, Beibei
    Yuan, Ying
    STATISTICS IN MEDICINE, 2015, 34 (10) : 1721 - 1732
  • [10] Bayesian dose-finding in phase I/II clinical trials using toxicity and efficacy odds ratios
    Yin, Guosheng
    Li, Yisheng
    Ji, Yuan
    BIOMETRICS, 2006, 62 (03) : 777 - 784